These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20000214)

  • 1. Rheumatoid arthritis. Understanding joint damage and inflammation.
    Capriotti T
    Adv Nurse Pract; 2007 May; 15(5):61-2, 64-6, 94. PubMed ID: 20000214
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Roos JC; Ostor AJ
    N Engl J Med; 2006 Nov; 355(19):2046-7; author reply 2048. PubMed ID: 17093259
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective T-cell costimulation modulation: a new approach to treating rheumatoid arthritis.
    Strand V
    Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):8, 13-4. PubMed ID: 17491581
    [No Abstract]   [Full Text] [Related]  

  • 5. Developments in the immunology of rheumatoid arthritis, a personal perspective.
    Panayi GS
    Rheumatology (Oxford); 2011 May; 50(5):815-7. PubMed ID: 21498557
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 7. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 8. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?
    Bobbio-Pallavicini F; Caporali R; Bugatti S; Montecucco C
    J Rheumatol; 2008 Oct; 35(10):1903-5. PubMed ID: 18843754
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of rheumatoid arthritis.
    Handa R
    Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

  • 11. Joint approach.
    Palmer K
    Minn Med; 2009 Sep; 92(9):22-5. PubMed ID: 19877473
    [No Abstract]   [Full Text] [Related]  

  • 12. [The latest aim of rheumatoid arthritis tratment is complete prevention of destruction].
    Krüger K
    MMW Fortschr Med; 2006 Oct; 148(42):31. PubMed ID: 17621796
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.
    Brulhart L; Ciurea A; Finckh A; Notter A; Waldburger JM; Kyburz D; Gabay C
    Ann Rheum Dis; 2006 Sep; 65(9):1255-7. PubMed ID: 16540545
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted therapies for patients with rheumatoid arthritis.
    Oliver S; Mooney J
    Prof Nurse; 2002 Aug; 17(12):716-20. PubMed ID: 12229045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early rheumatoid arthritis.
    Machold KP; Nell V; Stamm T; Aletaha D; Smolen JS
    Curr Opin Rheumatol; 2006 May; 18(3):282-8. PubMed ID: 16582693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R; Shealy D
    Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 20. Inflammation in juvenile idiopathic arthritis.
    Sullivan KE
    Pediatr Clin North Am; 2005 Apr; 52(2):335-57, v. PubMed ID: 15820371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.